The reality of low productivity of current pharmaceutical research in terms of new molecules and rising cost of development begs a fresh approach to creativity. This is coupled with major trust issues as a perceived lack of transparency which has eroded confidence in both pharmaceutical companies and the public institutions that regulate them.
|Title of host publication
|Value Creation in the Pharmaceutical Industry
|Alexander Schuhmacher, Markus Hinder, Oliver Gassmann
|Place of Publication
|Number of pages
|Published - 15 Jan 2016